Form 4 for GNLX GENELUX Corp
Accepted 2023-11-21 00:00:00 ET · period of report 2023-11-17 · accession 0001209191-23-056237 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-11-21 | 2023-11-17+ | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $11.61 | -18.1K | 102.6K | -15% | -$210.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-20 | S | D | 14,594 | $11.26 | 88,000 | D | — | — | (F2) The weighted average sale price for the transaction reported was $11.2554, and the range of prices were between $11.00 and $11.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2023-11-17 | S | D | 3,541 | $13.04 | 102,594 | D | — | — | (F1) The weighted average sale price for the transaction reported was $13.0386, and the range of prices were between $13.00 and $13.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |